Compare CVKD & XPON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVKD | XPON |
|---|---|---|
| Founded | 2022 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Electronic Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.7M | 6.2M |
| IPO Year | 2023 | 2022 |
| Metric | CVKD | XPON |
|---|---|---|
| Price | $6.90 | $0.75 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $32.00 | N/A |
| AVG Volume (30 Days) | 81.7K | ★ 225.6K |
| Earning Date | 11-10-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $9,417,947.00 |
| Revenue This Year | N/A | $61.26 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 109.37 |
| 52 Week Low | $6.75 | $0.60 |
| 52 Week High | $22.90 | $5.50 |
| Indicator | CVKD | XPON |
|---|---|---|
| Relative Strength Index (RSI) | 34.12 | 26.93 |
| Support Level | $6.75 | $0.83 |
| Resistance Level | $7.62 | $1.26 |
| Average True Range (ATR) | 0.96 | 0.08 |
| MACD | -0.18 | -0.02 |
| Stochastic Oscillator | 2.58 | 1.87 |
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
Expion360 Inc is focused on the design, assembly, manufacturing, and sales of lithium iron phosphate (LiFePO4) batteries and supporting accessories for recreational vehicles (RV's) and marine applications with plans to expand into home energy storage products and industrial applications. Its product offerings include some of the minimal-footprint batteries in the RV & Marine industry.